Study Evaluating the Addition of Fulvestrant to Erlotinib in Stage IIIB/IV Non-Small Cell Lung Cancer

Exclusion Criteria

• •Pregnant or breast-feeding women will not be entered on this study
• •Patients who are currently receiving another investigational drugs
• •Patients who are currently receiving other anti-cancer agents.
• •Hormone replacement therapy will not be allowed and have to be stopped 1 month prior to entry into the study
• •Patients who have an uncontrolled infection.
• •Patients receiving less than 100mg/day of erlotinib
• •Patients with evidence of progression after 2 months of erlotinib monotherapy.
• •Patients with a history of bleeding diathesis (i.e., disseminated intravascular coagulation \[DIC\], clotting factor deficiency) or long-term anticoagulant therapy (other than antiplatelet therapy).
• •Patients with a history of hypersensitivity to active or inactive excipients of fulvestrant (i.e. castor oil or Mannitol).
• •Patients who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study.